Table 1 Prevalence of allergic rhinitis in adults and its associated economic burden
Country | Prevalence | Direct cost | Indirect cost |
|---|---|---|---|
United States | 15–30% [3] | 3.4 billion USD per year [6] | 5.2 billion USD per year [6] |
Europe | 21% [2] | €159 to €554 per patient/year [6] | €2405 per untreated patient/year*[14] |
Sweden | 32% [15] | € 210 per patient/year [6] | €751 per patient/year [6] |
Spain | 11.4% [2] | € 554 per patient/year [6] | €1772 per person/year |
France | 13% [2] | €159 per patient/year [6] | €543 per patient/year [6] |
Turkey | 27.7% [16] | 79 USD per patient/year | Not available |
Korea | 13.3% [17] | 224 USD million/year [6] | 49 USD million/year [6] |
India | 20–30% [18] | 215 USD per patient/year [6] | 460 USD per patient/year[6] |
China | 16.8–23.9% [19] | € 195.6 patient/year [20] | € 440.9 patient/year [20] |
Malaysia | 21–24%[4] | Not available | Estimation: 2195 USD per patient per year[21] |